The Diagnostics Industry Post-Covid: A Revival or Return to Baseline?
The COVID-19 crisis shifted unprecedented resources to the diagnostics industry and presented a substantial growth opportunity for test manufacturers. A multitude of companies and entrepreneurs quickly pivoted toward developing innovative COVID tests, but whether they can survive post-pandemic exceptionalism remains to be seen.
The Diagnostics Industry Post-Covid: A Revival or Return to Baseline?
Published in MedTech Strategist
Authors: Wendy Diller, Oded Ben-Joseph, Craig Steger, and Thomas Joyce
Abstract:
The COVID-19 crisis shifted unprecedented resources to the diagnostics industry and presented a substantial growth opportunity for test manufacturers. A multitude of companies and entrepreneurs quickly pivoted toward developing innovative COVID tests, but whether they can survive post-pandemic exceptionalism remains to be seen.
News
Outcome Capital Launches Pharmacy and Related Services Advisory Board to Advance Innovation Across the Healthcare Sector
Thom Stambaugh, recognized leader in pharmacy innovation and care delivery transformation, will serve as inaugural member Boston, MA – November 12, 2025 — Outcome Capital, LLC, a highly specialized life sciences and healthcare advisory and investment banking firm, today announced the formation of its Pharmacy and Related Services Advisory Board, a new initiative within the […]
Read MoreResources
Outcome Capital Life Science Market Pulse, September 2025
Outcome Capital Life Science Market Pulse September 2025 Click to view our LifeSciences Pulse Newsletter
DownloadContact Us for More Information
Would you like to learn more about working with Outcome Capital or discuss your specific needs?
© Outcome Capital 2025. Member of Financial Industry Regulatory Authority (FINRA) and the Securities Investment Protection Corporation (SIPC). Check the background of this firm on FINRA’s BrokerCheck.
Outcome Capital and Outcome Life Sciences are affiliates of Outcome Holdings, LLC
Business Continuity Plan | Privacy Policy | Regulation Best Interest
